pharma
Pharma strategy that reads the science as closely as the numbers
We advise investors, drug makers and pharma services firms. Our work runs from originator to generic, and from prescription to consumer health. Our team includes doctors and scientists. So we can judge the science and the market together.
The molecule and the market
Pharma rewards those who understand both the molecule and the market. Patents expire. Payors push back on price. Pipelines disappoint more often than they deliver. Yet the sector keeps producing durable businesses that throw off cash: in originals, in generics and biosimilars, in consumer health, and in the services that keep the industry running.
We help clients tell the durable from the exposed. That means judging the science, the patent cliff and the payor picture together, not in separate workstreams.
Our pharma leads
News
